BioNTech has entered into a definitive agreement to acquire Biotheus, with the aim of enhancing the discovery and development of novel antibody therapies to address unmet medical needs in oncology and inflammatory diseases.Through this acquisition, BioNTech will gain full global rights to BNT327/PM8002, a late-stage clinical asset.

BioNTech已达成收购Biotheus的明确协议，旨在加强新型抗体疗法的发现和开发，以解决肿瘤学和炎症性疾病中未满足的医疗需求。通过此次收购，BioNTech将获得BNT327/PM8002（一种晚期临床资产）的全部全球权利。

This investigational bispecific antibody targets PD-L1 and VEGF-A, and clinical trials have demonstrated promising results, including in patients with PD-L1-low and -negative tumors who typically show limited response to current checkpoint inhibitor therapies.BNT327/PM8002 has the potential to redefine standards of care across multiple oncology indications, surpassing traditional checkpoint inhibitors.

这种研究性双特异性抗体靶向PD-L1和VEGF-A，临床试验已经证明了有希望的结果，包括PD-L1低和阴性肿瘤患者，这些患者通常对当前的检查点抑制剂疗法反应有限。BNT327/PM8002有可能超越传统的检查点抑制剂，重新定义多种肿瘤适应症的护理标准。

This asset is part of an innovative pipeline under development, supported by an advanced antibody discovery and development platform.To date, over 700 patients have been treated with BNT327/PM8002 in clinical trials, showing promising efficacy and tolerability across various tumor types. BioNTech plans to launch multiple registrational trials in 2024 and 2025, focusing on combinations of BNT327/PM8002 with chemotherapy for solid tumors, including small cell lung cancer, non-small cell lung cancer, and triple-negative breast cancer.The acquisition will also strengthen BioNTech’s presence in China, incorporating a local R&D hub for clinical trials and a state-of-the-art biologics manufacturing facility to support global production needs.

该资产是正在开发的创新管道的一部分，由先进的抗体发现和开发平台支持。。BioNTech计划在2024年和2025年启动多项注册试验，重点关注BNT327/PM8002与实体瘤化疗的组合，包括小细胞肺癌，非小细胞肺癌和三阴性乳腺癌。此次收购还将加强BioNTech在中国的业务，包括当地的临床试验研发中心和最先进的生物制剂生产设施，以支持全球生产需求。

Furthermore, more than 300 Biotheus employees in research, development, manufacturing, and supporting functions are expected to join BioNTech’s team. Source: biontech.de.

此外，预计有300多名从事研究、开发、制造和支持职能的Biotheus员工将加入BioNTech的团队。资料来源：biontech.de。